title: Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration.
abstract: OBJECTIVE
  The blood and prostatic concentrations of alfuzosin were determined in patients with benign prostatic hyperplasia (BPH).
  
  
  METHODS
  12 patients scheduled for BPH surgery were treated with alfuzosin 5 mg twice daily prior to surgery in an open trial. Seven doses were given over a 4-day period. Blood samples were drawn before the first and the last intake (day 3). On day 4 (surgery day), a blood and prostate tissue sample were taken simultaneously 12 hours after the last drug intake.
  
  
  RESULTS
  Mean trough blood levels were 6.0+/-4.6 ng/ml and 5.8+/-3.7 ng/ml on day 3 and day 4, respectively, indicating a stable alfuzosin concentration. The mean prostate concentration on day 4 was 12.3+/-5.6 ng/g. Alfuzosin prostate and blood concentrations at 12 hours post dosing on day 4 were significantly correlated (r=0.804, p=0.0016); the prostate-blood ratio was 2.4+/-0.7.
  
  
  CONCLUSIONS
  Oral administration of alfuzosin leads to a high diffusion of the drug into the prostate of BPH patients.
authors.affiliation: Urology Department, Central Hospital Gaston Doumergue, 5 Rue Hoche, 30029 Nimes Cedex 9, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Mottet
authors.forename: Françoise
authors.initials: F
authors.lastname: Bressolle
authors.forename: Vincent
authors.initials: V
authors.lastname: Delmas
authors.forename: Michèle
authors.initials: M
authors.lastname: Robert
authors.forename: Pierre
authors.initials: P
authors.lastname: Costa
mesh_terms: D000284:Administration, Oral; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D000368:Aged; D001682:Biological Availability; D001707:Biopsy, Needle; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011300:Preoperative Care; D011336:Probability; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D011799:Quinazolines / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D012720:Severity of Illness Index; D020728:Transurethral Resection of Prostate / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; C047638:alfuzosin